Bill & Melinda Gates Medical Research Institute initiates Phase 3 clinical trial of TB vaccine candidate

-- A large Phase 3 trial will evaluate whether the M72/AS01E vaccine candidate can protect adolescents and adults from pulmonary tuberculosis
-- Clinical trial site at University of the Witwatersrand, Johannesburg, South Africa, is first of up to 60 sites in seven countries
-- The M72/AS01E vaccine candidate could be the first new TB vaccine in 100 years if proven effective